1.An information management system of scientific research funds to be established and applied
Xiangyu WANG ; Lei QIAN ; Ping PING ; Jingwen DUAN ; Hong JIANG
Chinese Journal of Medical Science Research Management 2015;28(4):334-336
Following the increasing of amount and improving of management year by year,the management of scientific research funds must be informationized.We established an information management system of scientific research funds,according to the management standards of different departments which were the sources of funds.The system including two main modules.:budget management and expenditure management.The main functions of the system as follows:establishing the budget,expensing according to the budget,inquiring the feedback data,etc.The system increased the accuracy and effectiveness of management of scientific research funds.
2.Status and thinking of quality supervision on imported medicinal materials in shortage.
Jian-Guang ZHU ; Jin-Ao DUAN ; Wen-Lin LI ; Wei ZHOU ; Li-Li YANG
China Journal of Chinese Materia Medica 2018;43(12):2628-2632
With the continuous development of traditional Chinese medicine business, the types and amounts of Chinese materia medica resources are increasingly reduced. By reviewing the origins, trading sources, and existing quality standards of the available common Chinese madicinal materials in shortage, it was found that the large amount of imported medicinal materials in domestic market or clinical application were not due to the traditional paths such as envoys presenting tribute, business trade, war conflict, national migration, and tourist travel, but due to the shortage of resources in domestic origins. Meanwhile, the former quality control standard on traditional imported medicinal materials was out of date, and the new imported medicinal materials quality control standard was in absence, resulting in unclear origins, unknown origins and processing methods, as well as more and more prominent problems on mixed use of the different varieties with same name and the same varieties from different origins. On the one hand, this situation once again sounded the alarm for the development of Chinese medicine industry from the resource perspective. On the other hand, the confusion of new varieties in Chinese herbal medicine market has also brought a serious threat to the efficacy of Chinese medicine. It is pointed out that it is an effective way to ensure the drug safety of imported medicinal materials through strengthening quality supervision of shortage of traditional Chinese medicines based on the new pharmacopoeia standards.
3.Practice of Standardizing Rational Use of Proton Pump Inhibitors in Neurosurgery Department of Our Hospital by PDCA Cycle Management
Jianjie CHU ; Jialin DUAN ; Fang DOU ; Yuanyuan LI ; Weiwei LI ; Tingting FAN ; Xian ZHAO ; Jingwen WANG ; Aidong WEN
China Pharmacy 2019;30(1):10-14
OBJECTIVE: To promote rational use of proton pump inhibitors (PPIs) during perioperative period. METHODS: PDCA (Plan, Do, Check, Action) cycle management was used, the irrational use of PPIs of 300 medical records in neurosurgery department of our hospital were collected. The reasons were analyzed, management target was formulated and measures were implemented. The effects of management were evaluated through comparing the rate of irrational drug use and ratio of irrational type of PPIs in 300 medical records of neurosurgery department during perioperative period after management. RESULTS: Through collecting related data to confirm risk factors of stress ulcer, establishing rationality evaluation criteria for perioperative prophylactic use of PPIs, conducting rational drug use training among medical staff, drawing up various management systems and strengthening supervision and management, the rate of irrational use of PPIs was decreased significantly in our hospital; the number of irrational drug use cases decreased from 240 before management to 156 after management, among which the rate of prophylactic drug use without indication decreased from 37.33% to 29.00% (P<0.05); the irrational dosage rate decreased from 11.33% to 6.33% (P<0.05); the rate of irrational dosing frequency dropped from 12.67% to 5.00% (P<0.01). CONCLUSIONS: PDCA cycle management of our hospital can standardize the prophylactic use of PPIs in neurosurgery department during perioperative period and promote rational use of PPIs.
4.Buyang Huanwutang Treats Diabetic Peripheral Neuropathy via Mitochondrial Transport in Rats
Jiaxin TIAN ; Jingwen AN ; Tianya ZHANG ; Zhihong ZHANG ; Wang ZHANG ; Linchun SONG ; Tianmeng DUAN ; Ying BEN
Chinese Journal of Experimental Traditional Medical Formulae 2023;29(13):27-36
ObjectiveTo investigate the mechanism of Buyang Huanwutang in treating diabetic peripheral neuropathy (DPN) via mitochondrial transport. MethodDiabetes in SD rats was induced by a high-carbohydrate/high-fat diet and intraperitoneal injection of streptozotocin (STZ). The 45 diabetic rats were randomly assigned into a DPN group, an alpha-lipoic acid (60 mg·kg-1·d-1) group, and a Buyang Huanwutang (15 g·kg-1·d-1) group, with 15 rats in each group. Fifteen normal SD rats were fed with the standard diet and set as the control group. The rats were administrated with corresponding drugs by gavage for 12 weeks. The paw withdraw threshold (PWT) and motor nerve conduction velocity (MNCV) were measured at the end of medication, and the sciatic nerve and the bilateral dorsal root ganglia of L4-5 were collected. The injury model of NSC34 cells was established by treating with 50 mmol·L-1 glucose and 250 μmol·L-1 sodium palmitate. The NSC34 cells were then randomly assigned into a blank (10% blank serum) group, a DPN (10% blank serum) group, an apha-lipoic acid (10% apha-lipoic acid-containing serum) group, a Buyang Huanwutang (10% Buyang Huanwutang-containing serum) group, and a Buyang Huanwutang + Compound C (CC) (10% Buyang Huanwutang-containing serum + 10 μmol·L-1 CC) group. The cell intervention lasted for 24 h. The immunofluorescence method, immunohistochemistry, and Western blot were employed to determine the expression levels of phosphorylated adenosine monophosphate-activated protein kinase (p-AMPK), phosphorylated cAMP-response element binding protein (p-CREB), kinesin family member 5A (KIF5A), and dynein cytoplasmic 1 intermediate chain 2 (DYNC1I2). ResultCompared with the control group, the DPN group of rats showed increased fasting blood glucose (P<0.01), decreased MNCV and PWT (P<0.01), down-regulated expression of KIF5A, p-AMPK/AMPK, and p-CREB/CREB (P<0.01), and up-regulated expression of DYNC1I2 (P<0.01). Compared with the DPN group, drug intervention groups showed increased MNCV and PWT (P<0.01), up-regulated expression of KIF5A, p-AMPK/AMPK, and p-CREB/CREB (P<0.05, P<0.01), and down-regulated expression of DYNC1I2 (P<0.05, P<0.01). The Buyang Huanwutang group had higher levels of MNCV and KIF5A (P<0.05) and lower level of DYNC1I2 (P<0.01) than the apha-lipoic acid group. Compared with the blank group, the DPN group of NSC34 cells showed decreased levels of KIF5A, p-AMPK/AMPK, and p-CREB/CREB (P<0.01) and increased level of DYNC1I2 (P<0.01). The apha-lipoic acid group and Buyang Huanwutang group had higher levels of KIF5A, p-AMPK/AMPK, and p-CREB/CREB (P<0.05, P<0.01) and lower level of DYNC1I2 (P<0.01) in NSC34 cells than the DPN group. Buyang Huanwutang group had higher KIF5A level (P<0.05) in NSC34 cells than the apha-lipoic acid group. Moreover, the Buyang Huanwutang + CC group had lower levels of KIF5A, DYNC1I2, p-AMPK/AMPK, and p-CREB/CREB (P<0.01) in NSC34 cells than the Buyang Huanwutang group. ConclusionBuyang Huanwutang may regulate mitochondrial anterograde transport via the AMPK/CREB pathway to prevent and treat DPN.